AACR 2022 | The importance of a biomarker-directed approach in triple-negative breast cancer

Meenakshi Anurag, PhD, Baylor College of Medicine, Houston, TX, explains that breast cancer is a very heterogeneous disease consisting of the four intrinsic subtypes: luminal A, luminal B, HER2 enriched subtype, and basal-like subtype. The basal-like subtype is also called triple-negative breast cancer (TNBC) due to the absence of the typical breast cancer markers. This means that there are currently no targeted therapies for patients with TNBC. Stratification is therefore important to identify biomarkers that can indicate how a patient with TNBC can benefit from different therapies. This will allow patients with TNBC to be selective about treatments based on their molecular profile. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.